Slavka Hamulakova

Dr. Slavka Hamulakova

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2011 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Maria KozurkovaMaria Kozurkova
Maria Kozurkova
SHSlavka Hamulakova
Slavka Hamulakova
ZGZuzana Gazova
Zuzana Gazova
HPHelena Paulikova
Helena Paulikova
PKPavol Kristian
Pavol Kristian
The review summarizes research into the highly relevant topics of cholinesterase and amyloid aggregation inhibitors connected to tacrine congeners, both of which are associated with neurogenerative diseases. Various opinions will be discussed regarding the dual binding site inhibitors which are characterized by increased inhibitor potency against acetylcholin/butyrylcholine esterase and amyloid formation. It is suggested that these compounds can both raise levels of acetylcholine by binding to the active site, and also prevent amyloid aggregation. In connection with this problem, the mono/dual binding of the multifunctional derivatives of tacrine, their mode of action and their neuroprotective activities are reported. The influence of low molecular compounds on protein amyloid aggregation, which might be considered as a potential therapeutic strategy in the treatment of Alzheimer’s disease is also reported. Finally, attention is paid to some physico-chemical factors, such as desolvation energies describing the transfer of the substrate solvated by water, the metal-chelating properties of biometals reacting with amyloid precursor protein, amyloid beta peptide and tau protein.

1 September 2014 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SHSlavka Hamulakova
Slavka Hamulakova
JIJan Imrich
Jan Imrich
LJLadislav Janovec
Ladislav Janovec
PKPavol Kristian
Pavol Kristian
IDIvan Danihel
Ivan Danihel
KKKamil Kuca
Kamil Kuca

3 June 2024 in CNS Drugs
Verified
Journal Article
Open access
PDF file
AGAdrián Gucký
Adrián Gucký
SHSlavka Hamulakova
Slavka Hamulakova
Numerous physiological processes happening in the human body, including cerebral development and function, require the participation of biometal ions such as iron, copper, and zinc. Their dyshomeostasis may, however, contribute to the onset of Alzheimer’s disease (AD) and potentially other neurodegenerative diseases. Chelation of biometal ions is therefore a therapeutic strategy against AD. This review provides a survey of natural and synthetic chelating agents that are or could potentially be used to target the metal hypothesis of AD. Since metal dyshomeostasis is not the only pathological aspect of AD, and the nature of this disorder is very complex and multifactiorial, the most efficient therapeutics should target as many neurotoxic factors as possible. Various coumarin derivatives match this description and apart from being able to chelate metal ions, they exhibit the capacity to inhibit cholinesterases (ChEs) and monoamine oxidase B (MAO-B) while also possessing antioxidant, anti-inflammatory, and numerous other beneficial effects. Compounds based on the coumarin scaffold therefore represent a desirable class of anti-AD therapeutics.

1 September 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SHSlavka Hamulakova
Slavka Hamulakova
LJLadislav Janovec
Ladislav Janovec
MHMartina Hrabinova
Martina Hrabinova
PKPavol Kristian
Pavol Kristian
KKKamil Kuca
Kamil Kuca
JIJan Imrich
Jan Imrich

1 November 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SHSlavka Hamulakova
Slavka Hamulakova
LJLadislav Janovec
Ladislav Janovec
OSOndrej Soukup
Ondrej Soukup
DJDaniel Jun
Daniel Jun
KKKamil Kuca
Kamil Kuca

20 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
EKEva Konkoľová
Eva Konkoľová
Monika HudáčováMonika Hudáčová
Monika Hudáčová
SHSlavka Hamulakova
Slavka Hamulakova
Rastislav JendželovskýRastislav Jendželovský
Rastislav Jendželovský
JVJana Vargova
Jana Vargova
Maria KozurkovaMaria Kozurkova
Maria Kozurkova
A549 human lung carcinoma cell lines were treated with a series of new drugs with both tacrine and coumarin pharmacophores (derivatives 1a–2c) in order to test the compounds’ ability to inhibit both cancer cell growth and topoisomerase I and II activity. The ability of human topoisomerase I (hTOPI) and II to relax supercoiled plasmid DNA in the presence of various concentrations of the tacrine-coumarin hybrid molecules was studied with agarose gel electrophoresis. The biological activities of the derivatives were studied using MTT assays, clonogenic assays, cell cycle analysis and quantification of cell number and viability. The content and localization of the derivatives in the cells were analysed using flow cytometry and confocal microscopy. All of the studied compounds were found to have inhibited topoisomerase I activity completely. The effect of the tacrine-coumarin hybrid compounds on cancer cells is likely to be dependent on the length of the chain between the tacrine and coumarin moieties (1c, 1d = tacrine-(CH2)8–9-coumarin). The most active of the tested compounds, derivatives 1c and 1d, both display longer chains.